Redeye maintain its positive view on Railcare following the Q1 report. Market conditions are favorable, for the current year as well as longer-term. Machine sales have been impeded by travel restrictions lately, but we expect sales activity to gradually pick-up going forward. Our forecasts are virtually unchanged and we reiterate our Base case fair value of SEK 33 per share. This implies a significant potential from current share price level.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/